公开(公告)号：US20210405065A1

公开(公告)日：2021-12-30

申请号：US17479453

申请日：2021-09-20

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Joe TECTOR ,  Matt TECTOR

IPC: G01N33/68

Abstract: A method is provided for increasing the sensitivity of the complement-dependent cellular cytoxicity analysis that establishes whether a potential transplant recipient patient expresses donor organ-reactive antibodies that would reduce or prevent acceptance of the donor organ by a recipient. At least one gene encoding a complement inhibitor is inactivated in cells derived from a candidate transplant organ. Such modified cells, because they no longer produce at least one complement inhibitor, when placed in a serum sample from a potential transplant recipient, do not reduce the effective activity of serum complement. A lower level of recipient patient serum antibodies becomes effective in inducing detectable lysis of the donor cells.

公开(公告)号：US20210369713A1

公开(公告)日：2021-12-02

申请号：US17374100

申请日：2021-07-13

Applicant: SOUTHERN RESEARCH INSTITUTE ,  THE UAB RESEARCH FOUNDATION

Inventor： Corinne E. Augelli-Szafran ,  Omar Moukha-Chafiq ,  Mark J. Suto ,  Anath Shalev ,  Lance Thielen ,  Junqin Chen ,  Gu Jing

IPC: A61K31/517 ,  A61P1/16 ,  A61P3/06 ,  A61P3/10 ,  A61K31/5377

Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20210369683A1

公开(公告)日：2021-12-02

申请号：US17322260

申请日：2021-05-17

Applicant: VANDERBILT UNIVERSITY ,  The UAB Research Foundation ,  The United States of America, as Represented by the Secretary, Department of Health and Human Servic

Inventor： Matthew Hall ,  Daniel J. Urban ,  John Knight ,  Ross Holmes ,  Kyle David Wood ,  Alex Waterson ,  Victor M. Darley-Usmar ,  Leonard M. Neckers

IPC: A61K31/427 ,  A61K31/4439 ,  A61K31/506

Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.

公开(公告)号：US20210307601A1

公开(公告)日：2021-10-07

申请号：US17349546

申请日：2021-06-16

Applicant: The UAB Research Foundation

Inventor： John G. Edwards ,  Gregory R. Jackson

IPC: A61B3/06 ,  A61B3/02 ,  A61B3/00

Abstract: The present disclosure provides an improved method for photobleaching an eye of a subject. The disclosed method may be used in a number of psychophysical test methods, including, but not limited to, measurement of dark adaptation. The improved method for photobleaching involves at least one of the following improvements: (i) the use of a bleaching light emitting a particular wavelength of light or a tailored spectrum of wavelengths; (ii) restricting or otherwise spatially tailoring the region of the retina that is subject to photobleaching; and (iii) utilizing a bleaching light having an intensity that is at or below the intensity of ambient daylight. The present disclosure additionally provides a combination of a photobleaching light and an apparatus to administer a psychophysical test suitable for use in practicing the disclosed methods.

公开(公告)号：US20210268098A1

公开(公告)日：2021-09-02

申请号：US17264377

申请日：2019-08-02

Applicant: UAB Research Foundation

Inventor： Elena I. Frolova ,  IIya V. Frolov

IPC: A61K39/12 ,  C07K14/18 ,  C12N15/86 ,  A61P31/14

Abstract: The present invention provides an attenuated Old World alphavirus particle and methods of making same and using same as a vaccine and in gene therapy and immunotherapy methods.

公开(公告)号：US20210253676A1

公开(公告)日：2021-08-19

申请号：US17126396

申请日：2020-12-18

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Max D. Cooper ,  Brantley R. Herrin ,  Matthew N. Alder

IPC: C07K16/12 ,  C07K16/10 ,  C07K16/34

Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

公开(公告)号：US20210101861A1

公开(公告)日：2021-04-08

申请号：US17025404

申请日：2020-09-18

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Donald D. Muccio ,  Venkatram Reddy Atigadda ,  Wayne J. Brouillette ,  Clinton J. Grubbs ,  Jeonga Kim

IPC: C07C57/42 ,  C07C57/40 ,  C07C57/62 ,  A61K45/06 ,  C07C63/331 ,  C07C57/60 ,  C07D307/54 ,  C07C59/56 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P35/00

Abstract: Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.

公开(公告)号：US20210061863A1

公开(公告)日：2021-03-04

申请号：US17009536

申请日：2020-09-01

Applicant: University of Florida Research Foundation, Incorporated ,  The UAB Research Foundation

Inventor： Sergei Zolotukhin ,  Sanford L. Boye ,  Shannon E. Boye ,  Damien Marsic ,  Nicholas Muzyczka ,  Hector Ruben Mendez-Gomez ,  Paul E. Gamlin

IPC: C07K14/005 ,  C12N15/10 ,  C12N15/86

Abstract: Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (e.g., variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.

公开(公告)号：US10931094B2

公开(公告)日：2021-02-23

申请号：US16727227

申请日：2019-12-26

Applicant: The UAB Research Foundation

Inventor： Robert F. Arritt ,  Roger C. Dugan ,  Wayne E. Johnson ,  Gregory A. Franklin

IPC: H02H3/16 ,  H02P29/024 ,  H02H3/253 ,  G01R31/50 ,  G01R31/62 ,  G01R31/72 ,  H02H3/04

Abstract: A method for detecting an open-phase condition of a transformer having a grounded-wye high voltage side connection including monitoring current flowing in a neutral connection on the high voltage side of the transformer in real time by voltage relaying and current relaying to identify an open phase condition signature in a signal capable of characterizing change of current magnitude. A current signal may be injected onto the neutral terminal and the zero-sequence mode of the transformer monitored to detect an open-phase condition indicated by an increase in network impedance and decrease or elimination of the injection current.

公开(公告)号：US20210022605A1

公开(公告)日：2021-01-28

申请号：US16979657

申请日：2019-03-13

Applicant: THE UAB RESEARCH FOUNDATION

Inventor： Massimo Antonio Fazio ,  Christopher Antony Girkin

IPC: A61B3/12 ,  A61B3/10 ,  A61B3/16 ,  A61B3/00 ,  G06T7/00

Abstract: Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion changes in the retina are determined by colocalizing retinal perfusion data and optic nerve head (ONH) mechanical deformation data. Perfusion changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data. Optical coherence tomography-angiography (OCT-A) can be used to generate both retinal perfusion data and mechanical deformation data for an imaged volume. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature can be generated from the OCT-A imaging data and used to predict changes in blood perfusion in various areas of the retina due to IOP-induced mechanical deformations.